TDC
PETX

Thompson Davis & Co’s Aratana Therapeutics, Inc. PETX Stock Holding History

Thompson Davis & Co’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-500
Closed -$4K – 1250
2017
Q2 		$4K Buy
+500
New +$3.08K 0.01% 906

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Thompson Davis & Co's PETX Position: Q3 2017 in Review

Thompson Davis & Co sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2017, closing a stake of 500 shares — an estimated $4K sold.

Thompson Davis & Co first reported a position in PETX in Q2 2017 and held it in 1 quarter. The position peaked at $4K in Q2 2017. 96 funds tracked by Wall St. Rank hold PETX as of Q3 2017.

  • Thompson Davis & Co reported no remaining Aratana Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 500 Aratana Therapeutics, Inc. shares in Q3 2017, an estimated $4K.
  • Thompson Davis & Co first reported a position in Aratana Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
  • Thompson Davis & Co's Aratana Therapeutics, Inc. position peaked at $4K in Q2 2017.
  • 96 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2017.

Based on Thompson Davis & Co's 13F filing for Q3 2017, filed 30 Oct 2017.